Últimos Artículos de Lancet Diabetes & Endocrinology
- [Editorial] Redefining obesity: advancing care for better lives
- [Articles] Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort
- [Comment] Rating the response of primary aldosteronism to targeted medical treatment with the PAMO criteria
- [Review] Dissection of type 2 diabetes: a genetic perspective
- [Articles] Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
- [Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 619–30
- [Comment] Innovations in diabetic retinopathy screening in the UK
- [Comment] Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention
- [Correspondence] Evaluation of a type 2 diabetes remission programme
- [Correspondence] Evaluation of a type 2 diabetes remission programme – Authors' reply
- [Correspondence] Evaluation of a type 2 diabetes remission programme
- [In Focus] Food for thought
- [Correspondence] Bariatric surgery in children with obesity and type 2 diabetes
- [Comment] Barriers to care for refugees and migrants with diabetes
- [Articles] Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: a population-based study
- [Comment] Technology for type 1 diabetes: what impact will it have?
- [Review] Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
- [Editorial] The era of GLP-1 receptor agonists: costs versus benefits
- [Comment] The impact of the US election on diabetes
- [Correspondence] Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies